Université de Montréal, Montréal, Canada; Montreal Heart Institute, Montréal, Canada
Marc-André Legault
Université de Montréal, Montréal, Canada; Montreal Heart Institute, Montréal, Canada; Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montréal, Canada
Jean-Christophe Grenier
Montreal Heart Institute, Montréal, Canada
Rocio Sanchez
Montreal Heart Institute, Montréal, Canada
Eric Rhéaume
Université de Montréal, Montréal, Canada; Montreal Heart Institute, Montréal, Canada
Samira Asgari
Center for Data Sciences, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, United States
Amina Barhdadi
Montreal Heart Institute, Montréal, Canada; Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montréal, Canada
Yassamin Feroz Zada
Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montréal, Canada
Holly Trochet
Université de Montréal, Montréal, Canada; Montreal Heart Institute, Montréal, Canada
Yang Luo
Center for Data Sciences, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, United States
Leonid Lecca
Socios En Salud, Lima, Peru; Harvard Medical School, Boston, United States
Megan Murray
Center for Data Sciences, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States
Soumya Raychaudhuri
Center for Data Sciences, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, United States; Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; Department of Biomedical Informatics, Harvard Medical School, Boston, United States; Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, United States
Jean-Claude Tardif
Université de Montréal, Montréal, Canada; Montreal Heart Institute, Montréal, Canada
Université de Montréal, Montréal, Canada; Montreal Heart Institute, Montréal, Canada; Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montréal, Canada
Pharmacogenomic studies have revealed associations between rs1967309 in the adenylyl cyclase type 9 (ADCY9) gene and clinical responses to the cholesteryl ester transfer protein (CETP) modulator dalcetrapib, however, the mechanism behind this interaction is still unknown. Here, we characterized selective signals at the locus associated with the pharmacogenomic response in human populations and we show that rs1967309 region exhibits signatures of positive selection in several human populations. Furthermore, we identified a variant in CETP, rs158477, which is in long-range linkage disequilibrium with rs1967309 in the Peruvian population. The signal is mainly seen in males, a sex-specific result that is replicated in the LIMAA cohort of over 3400 Peruvians. Analyses of RNA-seq data further suggest an epistatic interaction on CETP expression levels between the two SNPs in multiple tissues, which also differs between males and females. We also detected interaction effects of the two SNPs with sex on cardiovascular phenotypes in the UK Biobank, in line with the sex-specific genotype associations found in Peruvians at these loci. We propose that ADCY9 and CETP coevolved during recent human evolution due to sex-specific selection, which points toward a biological link between dalcetrapib’s pharmacogene ADCY9 and its therapeutic target CETP.